InstalabLoading...
InstalabLoading...
If you are going through chemotherapy, taking strong immune-suppressing drugs, or recovering from major abdominal surgery, your stool culture may flag something most doctors rarely think about: Geotrichum. These yeasts usually live quietly in the gut and on the skin, but in a body whose defenses are down, they can move into the bloodstream, lungs, and other organs and cause infections that kill a substantial share of the people who get them.
This test looks for Geotrichum species in a stool sample. The result is qualitative: either the organism is detected or it is not. The clinical meaning depends almost entirely on who you are. In a healthy adult, finding Geotrichum is usually background noise. In an immunocompromised adult with persistent fever or pneumonia, the same finding can be the first clue to a life-threatening invasive fungal disease.
Geotrichum is a genus of yeast-like fungi that includes Geotrichum candidum and several closely related species (some of which have been reclassified into the Saprochaete and Magnusiomyces genera). They show up in soil, dairy products, and as part of the normal flora of the human mouth, skin, and digestive tract. Detection in a stool sample tells you the organism is present in your gut. It does not, by itself, mean you are sick.
The reason this test matters is what these yeasts can do when the immune system is suppressed. In published case series, Geotrichum has caused bloodstream infections (fungemia) and disease in the lungs, liver, spleen, central nervous system, and kidneys, almost always in people with blood cancers, neutropenia (very low neutrophil counts), or other forms of severe immune suppression.
Across the published evidence, invasive Geotrichum disease clusters in a narrow population. The international FungiScope registry of 23 invasive Saprochaete and Geotrichum cases, a French multicenter study of 36 critically ill patients, and Mexican and Italian case series all describe the same picture: adults with blood cancers, recent chemotherapy, and neutropenia (low neutrophil counts that leave the body unable to fight off fungi).
In the French ICU series of 36 critically ill patients, Geotrichum was isolated early after admission and ICU mortality reached 67%. In a Texas cancer center analysis of rare yeast bloodstream infections, central venous catheters were a common entry point, and disseminated infection carried very high mortality. A separate study of oral yeasts in 245 people with substance use disorders in Iran found Geotrichum and Magnusiomyces species among the rare oral colonizers, but did not link this colonization to outcomes.
Invasive Geotrichum infections are rare, but when they happen, they are deadly. Mortality has been roughly 39% to 45% in two Mexican referral-center series of 18 and 20 patients, and 65% in the international FungiScope registry of 23 cases, despite antifungal therapy. The French ICU study reported 67% mortality among critically ill patients.
Treatment choice appears to matter. In the FungiScope registry, most isolates had very high minimum inhibitory concentrations (a lab measure of how much drug it takes to stop the yeast from growing) for echinocandins (an antifungal drug class that includes caspofungin and micafungin). Patients started on echinocandins had worse 30-day outcomes than patients started on amphotericin B with or without flucytosine, or on azole drugs such as voriconazole. The authors concluded echinocandins are not an option for these infections.
Stool detection of Geotrichum tells you the organism is present in your gut. It does not tell you whether the yeast has invaded tissue. Two blood tests are commonly used to screen for invasive fungal disease, and they perform very differently for Geotrichum.
In a retrospective evaluation of 38 invasive Geotrichum and Magnusiomyces infections, serum beta-1,3-D-glucan (a piece of the fungal cell wall released into the blood during invasive disease) caught roughly 65 out of 100 cases (sensitivity 65%) and correctly cleared 96 out of 100 patients without infection (specificity 96%). Galactomannan, the standard antigen test for invasive aspergillosis, was 0% sensitive: it never turned positive in any of the Geotrichum cases studied. If you are at risk for invasive fungal disease and your galactomannan is negative, that does not rule out Geotrichum.
Geotrichum stool testing is qualitative. There are no published clinical thresholds, optimal counts, or longevity-focused targets for this organism. The result is reported as detected or not detected. No study has defined what fungal load constitutes harmless colonization versus pathogenic overgrowth, and no guideline body recommends acting on a positive stool result in an asymptomatic, immunocompetent adult.
| Result | What It Means |
|---|---|
| Not Detected | Geotrichum is not present at detectable levels in this stool sample. This is the expected finding in most healthy adults. |
| Detected | Geotrichum is present in the gut. Clinical significance depends on your immune status, symptoms, and other testing. |
Compare results within the same lab over time, since detection methods and sensitivity can vary between labs.
For most healthy adults, a single negative result is reassuring and serial testing has limited value. For people on chronic immune suppression, undergoing chemotherapy, or recovering from major abdominal surgery, the picture changes. A baseline stool study can document what is living in your gut before high-risk treatment begins, and a repeat test during or after treatment can flag whether new fungal species have taken hold.
A reasonable cadence is a baseline test before any planned immunosuppressive therapy, a follow-up if you develop persistent fever, unexplained pneumonia, or other symptoms during treatment, and an annual check if you remain on long-term immune-suppressing medication. Single readings in symptomatic, high-risk patients should not wait for a trend; they need to be acted on quickly.
A positive Geotrichum result in stool means different things in different bodies. If you are healthy, with no fever, no respiratory symptoms, and an intact immune system, the finding is likely incidental colonization and does not require antifungal treatment. If you are immunocompromised or critically ill, the same result deserves urgent evaluation by an infectious disease specialist.
Useful companion tests include serum beta-1,3-D-glucan to screen for invasive disease, blood cultures (with specific attention to fungal isolation), chest imaging if you have any respiratory symptoms, and a complete blood count to assess neutrophil levels. If your beta-1,3-D-glucan is positive alongside detection in stool, and you have fever or respiratory symptoms in the setting of immune suppression, that pattern warrants empiric antifungal therapy and a workup for disseminated infection. Echinocandins should not be used as first-line treatment for confirmed invasive Geotrichum disease.
Geotrichum Species is best interpreted alongside these tests.